Sarepta Therapeutics, Inc. SRPT

What this company does

Sarepta Therapeutics, Inc. has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection, AMONDYS 45 (casimersen) Injection, and ELEVIDYS. As of December 31, 2025, it had 835 employees globally, 49% of whom held advanced degrees, with 71% engaged directly in research and development activities and 29% in selling and general and administration. It launched its first commercial product, EXONDYS 51, in 2016, for the treatment of Duchenne in patients with a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping. It launched VYONDYS 53 in 2019 for the treatment of Duchenne in patients with a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. It launched AMONDYS 45 in 2021 for the treatment of Duchenne in patients with a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping. ELEVIDYS was granted accelerated approval from the FDA in June 2023 for the treatment of ambulatory patients aged four through five years with Duchenne with a confirmed mutation in the Duchenne gene. It was originally incorporated in the State of Oregon on July 22, 1980, and reincorporated in the State of Delaware on June 6, 2013.

Written from the business description in Sarepta Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.